Castle Biosciences Inc., a company focused on improving health through innovative tests, announced the approval of new compensation terms involving restricted stock units (RSUs) for 66 employees. On June 14, 2025, the Compensation Committee of the Board of Directors granted RSUs covering a total of 135,978 shares of common stock as part of the company's 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a period of four years, with 25% vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in three equal annual installments, contingent on continued employment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.